Catheter ablation added to anticoagulation therapy did not significantly reduce recurrent stroke or major cardiovascular outcomes in atrial fibrillation patients.
2
The STABLED trial enrolled 251 patients with ischemic stroke and atrial fibrillation, comparing standard therapy to ablation plus standard therapy.
3
Primary outcomes showed similar event rates for recurrent ischemic stroke, hospitalization for heart failure, and all-cause death between both treatment groups.
4
Secondary outcomes indicated comparable event counts, with some bleeding complications more frequent in the ablation group.
5
The study's findings suggest no clear clinical benefit of catheter ablation in this population, with limitations affecting generalizability.
